All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy and is characterized by the neoplastic proliferation of plasma cells.1 While continued research and the development of new treatments for MM have improved survival rates of patients, it is becoming increasingly important to address dietary and lifestyle factors in order to maximize positive clinical outcomes. In particular, diet and microbiome composition play key roles in the absorption and utilization of energy gained from nutritional intake, whilst influencing immunologic stimuli and the regulation of cytokine secretion in intestinal epithelial cells.
Existing and emerging data clearly demonstrate the impact of changes in the gut microbiome on the development of certain malignancies through increased inflammation and other host-microbiome interactions.1
Recently, Shah et al.1 published a review of current evidence on diet and the microbiome as potential modifiers of MM risk and the mechanisms by which these factors may influence disease development and progression. We summarize the key findings here.
Diet remains one of the major modifiable risk factors for cancer. Several dietary components have been shown to significantly influence the risk of developing MM, as summarized in Figure 1. The effects of certain vitamins and minerals on MM risk are outlined in Figure 2.
Figure 1. Influence of individual dietary components on MM*
GI, glycemic index; IGF-1, insulin growth factor-1; IL-6, interleukin-6; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma.
*Adapted from Shah, et al.1
Figure 2. Influence of vitamins and minerals on MM*
IGF-1, insulin growth factor-1; IL-6, interleukin-6; ISS, International Staging System; MM, multiple myeloma; NF-kB, nuclear factor-kappa B.
*Adapted from Shah, et al.1
The risk of MM has been shown to be lower in individuals who eat a plant-based diet when compared with meat eaters. The consumption of fruit, cruciferous vegetables, fish, and whole grains have all been shown to reduce the risk of MM. Patients diagnosed with MM consistently present with a vitamin D deficiency, which negatively impacts myeloma activity, bone turnover, and survival outcomes. Dysregulation of the microbiome is regularly observed in patients with MM, and several studies are currently investigating the effects of diet and supplementation, with a particular emphasis on increasing butyrate-producing bacteria.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox